Vividion rectifiers names Jenna Goldberg as Chief Medical Officer
Vividion rectifiers,Inc., a biopharmaceutical company exercising new discovery technologies to unleash high value, traditionally undruggable targets with perfection rectifiers for ruinous cancers and vulnerable diseases, and a wholly possessed and singly operated attachment of Bayer AG, moment blazoned that Jenna Goldberg,M.D., has joined the company as Chief Medical Officer.Dr. Goldberg brings assiduity leadership experience to Vividion, having held multiple elderly medical places during her career at Janssen Research and Development, a division of Johnson & Johnson.
“ Jenna has a broad and successful track record in medicine development, having advanced several new curatives through blessing with focus and perfection, thereby enabling cases in need to profit from cancer improvements. Jenna brings proven leadership chops, clinical development moxie and tremendous energy to our growing platoon, ” said Jeffrey Hatfield, principal administrative officer of Vividion. “ Her addition comes at an instigative curve point for our growth, as we easily see the eventuality to advance multiple programs into the clinic starting coming time. ”
“ I’m veritably agitated to join Vividion to continue to advance invention in an entrepreneurial terrain concentrated on patient benefits and issues, ” saidDr. Goldberg. “ I’m impressed by the channel’s breadth of novel, first- by- class programs in oncology and immunology. These programs are nearly all targeting proteins the assiduity has preliminarily viewed as undruggable, and indicate the eventuality to deliver enormous value to cases if successful. I’m also intrigued by the arm’s length business model established with Bayer that allows us to operate largely autonomously and singly but with the specialized moxie and fiscal stability of a major pharmaceutical company. ”
Dr. Goldberg has served most lately as Vice President, Early Clinical Development, at Janssen supervising the clinical programs for multiple myeloma, cellular remedy, prostate cancer, as well as clinical pharmacology. also, she served as theCo-Chair of Janssen Oncology Protocol Review Committee, since January 2021. specially,Dr. Goldberg supervised protocol developments, successful IND cessions of multitudinous composites, and all early development clinical sweats for teclistamab, talquetamab, and ciltacabtagene autoleucel, that were either granted advance remedy designation or are presently approved drugs. Dr Goldberg also held other beforehand as well as late development medical places at Janssen over the once eight times. Prior to joining Janssen, she served as Assistant Attending Physician at Memorial Hospital/ Assistant Member of Memorial Sloan- Kettering Cancer Center.Dr. Goldberg holds anM.D. from Johns Hopkins University School of Medicine and an undergraduate from Massachusetts Institute of Technology, with a Bachelorette of Science in Biology.Dr. Goldberg did her postdoctoral training as a Fellow at Memorial Sloan Kettering, Cancer Center in Hematology and Oncology as well as a Fellow in Medicine, at Weill Medical College of Cornell University.
Vividion rectifiers,Inc. a wholly possessed and singly operated attachment of Bayer AG acquired in August 2021, is a biopharmaceutical company exercising new discovery technologies to unleash high value, traditionally undruggable targets with perfection rectifiers for ruinous cancers and vulnerable diseases. The company’s platform has enabled it to identify hundreds of preliminarily unknown functional pockets on well- validated protein targets intertwined in a wide range of conditions, while contemporaneously relating composites from its personal covalent chemistry library that interact in a largely picky manner with those pockets. The company is using its personal chemoproteomic platform to advance a diversified channel of largely picky small patch rectifiers targeting high value, traditionally undruggable targets in oncology and immunology. For further information, please visitwww.vividion.com.
Bayer is a global enterprise with core capabilities in the life wisdom fields of health care and nutrition. Its products and services are designed to help people and the earth thrive by supporting sweats to master the major challenges presented by a growing and growing global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and produce value through invention and growth. The Bayer brand stands for trust, trustability and quality throughout the world. In financial 2021, the Group employed around,000 people and had deals of44.1 billion euros. R&D charges, before special particulars, amounted to5.3 billion euros.